Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Friday, July 24th. The stock was sold at an average price of $531.74, for a total transaction of $5,051,530.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $172,519,320.82. The trade was a 2.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Trading Up 0.2%

Shares of UTHR stock opened at $524.70 on Thursday. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35. The business’s fifty day simple moving average is $545.45 and its 200-day simple moving average is $532.24. The company has a market cap of $22.27 billion, a PE ratio of 19.37, a PEG ratio of 1.75 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same quarter last year, the business posted $6.63 earnings per share. On average, equities analysts forecast that United Therapeutics Corporation will post 26.65 earnings per share for the current year.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Promising ralinepag trial results: The Lancet published full results from United Therapeutics’ ADVANCE OUTCOMES study. Investigational pulmonary arterial hypertension treatment ralinepag reduced the risk of clinical worsening by 55% versus placebo, improving the company’s potential pipeline outlook. Ralinepag is not yet approved by the FDA, so regulatory and commercialization risks remain. United Therapeutics Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet
• Positive Sentiment: Analyst support remains strong: Eleven analysts rate UTHR a Buy and two rate it a Hold, producing a consensus “Moderate Buy” rating. The average price target is $648.33, with JPMorgan recently raising its target to $687 and HC Wainwright increasing its target to $660. United Therapeutics Given Average Rating of Moderate Buy by Brokerages
• Neutral Sentiment: Institutional ownership is high: Hedge funds and other institutional investors own approximately 94.1% of UTHR’s shares. Several institutions increased their positions during the second quarter, signaling continued professional-investor interest, although this does not guarantee further gains. United Therapeutics Insider Trading Report
• Negative Sentiment: CEO stock sale may pressure sentiment: CEO Martine Rothblatt sold 9,500 shares for roughly $5.04 million, reducing her direct stake by 2.84%. She still owns a substantial position, so the transaction may reflect liquidity or diversification rather than a negative view of the business, but insider selling can weigh on investor confidence. Insider Selling United Therapeutics CEO Sells Stock
• Negative Sentiment: Recent operating results were below expectations: United Therapeutics previously reported quarterly earnings and revenue below consensus, with revenue declining 1.6% year over year. That performance remains a concern despite the company’s strong profitability and promising pipeline.

Hedge Funds Weigh In On United Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in UTHR. Torren Management LLC acquired a new position in shares of United Therapeutics during the 4th quarter valued at about $26,000. Activest Wealth Management increased its holdings in shares of United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares during the last quarter. Entrust Financial LLC purchased a new stake in United Therapeutics in the fourth quarter valued at $31,000. International Assets Investment Management LLC raised its holdings in United Therapeutics by 426.7% in the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 64 shares during the period. Finally, Wilmington Savings Fund Society FSB lifted its holdings in shares of United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 49 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Royal Bank Of Canada lifted their target price on United Therapeutics from $701.00 to $704.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. Morgan Stanley set a $516.00 price target on United Therapeutics in a research report on Thursday, May 7th. JPMorgan Chase & Co. increased their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Bank of America cut their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. Finally, Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $648.33.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.